

BIOCON GROUP

FACT SHEET

December - 2016

BIOCON LIMITED (CONSOLIDATED)**BALANCE SHEET****(Rs Cr)**

	December 31, 2016	March 31, 2016
ASSETS		
Non-current assets		
(a) Property, plant and equipment	1,763	1,681
(b) Capital work-in-progress	2,330	2,062
(c) Investment property	1	1
(d) Goodwill	26	26
(e) Other intangible assets	46	41
(f) Intangible assets under development	296	180
(g) Investments in associates and a joint venture	43	32
(h) Financial assets		
Loans and advances	30	31
Other financial assets	111	114
(i) Income tax asset, net	91	91
(j) Deferred tax asset, net	70	74
(k) Other non-current assets	240	234
	5,047	4,567
Current assets		
(a) Inventories	604	542
(b) Financial assets		
Investments	441	432
Trade receivables	907	712
Cash and cash equivalents	551	1,123
Other bank balances	1,260	805
Other financial assets	238	233
(c) Other current assets	167	65
	4,168	3,912
TOTAL	9,215	8,479
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	100	100
(b) Other equity	4,528	3,958
Equity attributable to equity holders of the Company	4,628	4,058
Non-controlling interest	352	286
	4,980	4,344
Non-current liabilities		
(a) Financial liabilities		
Borrowings	2,230	2,072
Other financial liabilities	8	19
(b) Provisions	35	30
(c) Other non-current liabilities	364	371
	2,637	2,492
Current liabilities		
(a) Financial liabilities		
Borrowings	315	395
Trade payables	695	524
Other financial liabilities	327	296
(b) Short-term provision	46	37
(c) Income tax liability, net	113	75
(d) Other current liabilities	102	316
	1,598	1,643
TOTAL	9,215	8,479

BIOCON LIMITED (CONSOLIDATED)								
PROFIT & LOSS STATEMENT								
(Rs. Cr)								
Particulars	9M - FY17			9M - FY16			Variance IGAAP	Variance IndAS
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS		
INCOME								
Biocon	1,982	102	2,084	1,737	(89)	1,648	14%	27%
Small molecules	1,121	78	1,199	977	15	992	15%	21%
Biologics	322	16	338	237	(15)	222	36%	52%
Branded formulations	419	(1)	418	425	(89)	336	-2%	24%
Licensing#	120	9	129	98	-	98	24%	33%
Syngene - Research Services	866	-	866	744	-	744	16%	16%
Total Sales	2,848	102	2,950	2,481	(89)	2,392	15%	23%
Other income	158	9	167	87	8	95	80%	74%
TOTAL REVENUE	3,006	111	3,117	2,568	(81)	2,487	17%	25%
EXPENDITURE								
Material & Power costs	1,183	45	1,228	1,085	(11)	1,074	9%	14%
Staff costs	504	5	509	424	(19)	405	19%	26%
Research & Development expenses*	201	-	201	175	(1)	174	15%	15%
Other expenses	263	10	273	217	(10)	207	21%	31%
Manufacturing, staff & other expenses	2,151	60	2,211	1,901	(41)	1,860	13%	19%
EBITDA	855	51	906	667	(40)	627	28%	45%
Interest & Finance charges	21	-	21	9	-	9	139%	139%
Depreciation & Amortisation	199	6	205	180	4	184	11%	11%
Share of profit in JV	(11)	-	(11)	-	(16)	(16)	-	-34%
PBT BEFORE EXCEPTIONAL ITEM	646	45	691	478	(28)	450	35%	54%
Exceptional item, Net	-	-	-	307	(415)	(108)	-	-
PBT	646	45	691	785	(443)	342	-18%	102%
Taxes	135	16	151	95	(7)	88	43%	73%
Taxes on exceptional item	-	-	-	104	(104)	-	-	-
NET PROFIT BEFORE MINORITY INTEREST	511	29	540	586	(332)	254	-13%	112%
Minority interest	54	1	55	51	(14)	37	5%	48%
NET PROFIT FOR THE PERIOD	457	28	485	535	(318)	217	-15%	123%
EPS Rs.	22.9		24.3	26.8		10.9		
NET PROFIT BEFORE EXCEPTIONAL ITEM	457	28	485	332	(7)	325	38%	49%
Exceptional item, net of taxes	-	-	-	203	(311)	(108)		
NET PROFIT FOR THE PERIOD	457	28	485	535	(318)	217	-15%	123%
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>								
<i># Including one time compensation from customer during Q1 - FY16</i>								
<i>* Gross Research & Development expenses</i>								
			304			275		

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Cr)

Particulars	Q3 - FY17			Q3 - FY16			Variance IGAAP	Variance IndAS
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS		
INCOME								
Biocon	705	7	712	558	(32)	526	26%	35%
Small molecules	383	7	390	318	(3)	315	20%	24%
Biologics	120	-	120	80	(5)	75	51%	61%
Branded formulations	123	-	123	128	(24)	104	-4%	18%
Licensing#	79	-	79	32	-	32	147%	148%
Syngene - Research Services	317	-	317	270	-	270	17%	17%
Total Sales	1,022	7	1,029	828	(32)	796	23%	29%
Other income	59	4	63	25	8	33	136%	88%
TOTAL REVENUE	1,081	11	1,092	853	(24)	829	27%	32%
EXPENDITURE								
Material & Power costs	407	-	407	354	(10)	344	15%	18%
Staff costs	177	2	179	146	(7)	139	21%	29%
Research & Development expenses*	85	-	85	68	-	68	25%	25%
Other expenses	90	7	97	76	(4)	72	17%	34%
Manufacturing, staff & other expenses	759	9	768	644	(21)	623	18%	23%
EBITDA	322	2	324	209	(3)	206	54%	57%
Interest & Finance charges	9	-	9	2	-	2	487%	487%
Depreciation & Amortisation	69	2	71	62	2	64	10%	10%
Share of profit in JV	(1)	-	(1)	-	(3)	(3)	-	-69%
PBT BEFORE EXCEPTIONAL ITEM	245	-	245	145	(2)	143	69%	71%
Exceptional item, Net	-	-	-	-	-	-	-	-
PBT	245	-	245	145	(2)	143	69%	71%
Taxes	54	1	55	24	(2)	22	122%	150%
Taxes on exceptional item	-	-	-	-	-	-	-	-
NET PROFIT BEFORE MINORITY INTEREST	191	(1)	190	121	-	121	58%	57%
Minority interest	19	-	19	18	(1)	17	8%	10%
NET PROFIT FOR THE PERIOD	172	(1)	171	103	1	104	67%	65%
EPS Rs.	8.6		8.6	5.2		5.2		

Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers

* Gross Research & Development expenses

100

91

BIOCON LIMITED (CONSOLIDATED)								
PROFIT & LOSS STATEMENT								
(Rs. Cr)								
Particulars	Q3 - FY17			Q2 - FY17			Variance IGAAP	Variance IndAS
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS		
INCOME								
Biocon	705	7	712	637	17	654	11%	9%
Small molecules	383	7	390	380	9	389	1%	0%
Biologics	120	-	120	96	-	96	24%	24%
Branded formulations	123	-	123	137	(1)	136	-10%	-10%
Licensing	79	-	79	24	9	33	225%	142%
Syngene - Research Services	317	-	317	286	-	286	11%	11%
Total Sales	1,022	7	1,029	923	17	940	11%	9%
Other income	59	4	63	50	3	53	19%	20%
TOTAL REVENUE	1,081	11	1,092	973	20	993	11%	10%
EXPENDITURE								
Material & Power costs	407	-	407	382	1	383	6%	6%
Staff costs	177	2	179	164	2	166	8%	8%
Research & Development expenses*	85	-	85	65	-	65	30%	30%
Other expenses	90	7	97	99	2	101	-9%	-4%
Manufacturing, staff & other expenses	759	9	768	710	5	715	7%	8%
EBITDA	322	2	324	263	15	278	23%	16%
Interest & Finance charges	9	-	9	7	-	7	35%	35%
Depreciation & Amortisation	69	2	71	66	2	68	3%	3%
Share of profit in JV	(1)	-	(1)	(5)	-	(5)	-	-83%
PBT BEFORE EXCEPTIONAL ITEM	245	-	245	195	13	208	26%	18%
Exceptional item, Net	-	-	-	-	-	-	-	-
PBT	245	-	245	195	13	208	26%	18%
Taxes	54	1	55	39	2	41	38%	30%
Taxes on exceptional item	-	-	-	-	-	-	-	-
NET PROFIT BEFORE MINORITY INTEREST	191	(1)	190	156	11	167	23%	15%
Minority interest	19	-	19	18	1	19	6%	-2%
NET PROFIT FOR THE PERIOD	172	(1)	171	138	10	148	26%	17%
EPS Rs.	8.6		8.6	6.9		7.4		
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>								
* Gross Research & Development expenses			100			113		